PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025

Summary

Global HIV therapeutics market was worth approximately US$16.3 billion in 2015, and GlobalData projects this market to reach a total of US$22.5 billion in sales by 2025, at a Compound Annual Growth Rate (CAGR) of 3.3%.

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART).

Some of the main drivers of the growth of the HIV market during the forecast period are expected to be –
– The introduction of novel drugs-most notably, single-tablet regimens (STRs) and nucleotide reverse transcriptase inhibitor (NRTI)-free regimens with improved tolerability, a reduced pill burden, or increased efficacy.
– An increasing number of people living with HIV who are treated with antiretroviral therapy (ART).
– Increased efforts to identify new HIV infections through more aggressive screening and diagnostic policies, along with new and more sensitive diagnostic testing tools and methods.
– Adoption of the test-and-treat approach to increase the number of patients on ART and reduce viral loads.

HIV market is dominated by the Big Pharma players, such as Gilead, ViiV Healthcare (a collaboration between GlaxoSmithKline [GSK], Pfizer, and Shionogi), Janssen, and Merck, and other companies that have carved out a niche in the existing marketplace. While some of the companies involved in the HIV marketplace have invested in their R&D to build exhaustive pipelines spanning all phases of clinical development, others, such as Bristol-Myers Squibb (BMS), moved out of the HIV market in favor of other disease markets, such as oncology.

Two of the most important persistent unmet needs with regard to the current HIV therapies are concerns about drug adverse effects and the need for drugs that are active against drug-resistant strains of HIV. Currently, it is relatively common for drug-resistant viral strains to force physicians to move patients from one therapy to the next, which can result in in the emergence of untreatable strains and restrict the use of the available drugs. This is especially a concern among patients who are treated with a multi-pill regimen, which negatively affects compliance rates.

The report “PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025” provides an overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following –
– Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Gilead Sciences, ViiV Healthcare,Merck & Co. , Janssen (Johnson & Johnson), Bristol-Myers Squibb, TaiMed Biologics, Cytodyn.

Scope

– Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.